Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €18.77 EUR
Change Today +0.175 / 0.94%
Volume 0.0
LDB On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
Stuttgart
OTC US
As of 3:21 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (LDB) Snapshot

Open
€18.68
Previous Close
€18.60
Day High
€19.18
Day Low
€18.68
52 Week High
03/27/14 - €22.97
52 Week Low
10/15/14 - €14.94
Market Cap
3.7B
Average Volume 10 Days
55.0
EPS TTM
--
Shares Outstanding
196.4M
EX-Date
03/26/15
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for H LUNDBECK A/S (LDB)

Related News

No related news articles were found.

h lundbeck a/s (LDB) Details

H. Lundbeck A/S researches, develops, produces, and sells pharmaceuticals for the treatment of brain disorders in Denmark and internationally. The company offers pharmaceutical products for the treatment of schizophrenia, major depressive disorder, symptomatic neurogenic orthostatic hypotension, lennox-gastaut syndrome, and alcohol dependence. It also offers other products for the treatment of Alzheimer’s disease, depression and anxiety, Parkinson’s disease, chorea associated with Huntington’s disease, relapsed indolent B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, manic episodes associated with bipolar 1 disorder, and refractory complex partial seizures. In addition, the company is involved in the development of Brexpiprazole, a novel investigational psychotherapeutic compound; and Idalopirdine, a potent and selective 5-HT6 receptor antagonist that are in Phase III clinical trails. It has strategic alliances with various companies, including Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited. The company was founded in 1915 and is headquartered in Valby, Denmark.

5,811 Employees
Last Reported Date: 02/5/15
Founded in 1915

h lundbeck a/s (LDB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (LDB) Key Developments

H. Lundbeck A/S Approves Board Changes

H. Lundbeck A/S announced at its annual general meeting held on March 25, 2015, it approved the Lene Skole, Jesper Ovesen and Lars Holmqvist were elected to the board of directors. Christian Dyvig, Thorleif Krarup and Melanie Lee did not stand for re-election.

H. Lundbeck A/S - Shareholder/Analyst Call

Annual General Meeting

H. Lundbeck A/S Proposes Not to Pay Dividend for 2014

H. Lundbeck A/S at the annual general meeting to be held on 25 March 2015 proposed no dividend payout for 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LDB:GR €18.77 EUR +0.175

LDB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $62.94 USD +0.48
Depomed Inc $21.87 USD -0.45
Emergent Biosolutions Inc $27.85 USD +0.24
Lupin Ltd 1,955 INR -18.15
Salix Pharmaceuticals Ltd $172.63 USD +0.08
View Industry Companies
 

Industry Analysis

LDB

Industry Average

Valuation LDB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit www.lundbeck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.